Hualun Biologicals

Hualan Biological Engineering is a leading Chinese biopharmaceutical company specializing in the research, development, and manufacturing of plasma-derived products and vaccines. Founded in 1992 and headquartered in Xinxiang, Henan, the company is one of the largest producers of human albumin, intravenous immunoglobulin, and coagulation factors in China. Its vaccine division, Hualan Biological Bacterin, is a major supplier of influenza vaccines, including the first quadrivalent influenza vaccine approved in China. Additionally, the company has expanded into the monoclonal antibody space through its subsidiary Hualan Genetic, targeting oncology and autoimmune diseases with a robust pipeline of biosimilars. Hualan is publicly traded on the Shenzhen Stock Exchange and is a critical component of China's healthcare infrastructure.